Basal Cell Carcinoma
Basal cell carcinoma (BCC) is the most prevalent form of skin cancer and the most commonly diagnosed malignancy in humans. It arises from basal keratinocytes located in the stratum basale of the epidermis or the outer root sheath of hair follicles. BCC primarily affects sun-exposed areas of the skin, particularly the head and neck, and has a strong correlation with cumulative ultraviolet (UV) radiation exposure. Despite being classified as malignant, BCC is characterized by its slow growth, rare metastatic potential, and excellent prognosis when properly treated. However, it can be locally invasive, destructive, and disfiguring if neglected.
Symptoms
BCC typically presents as a slowly enlarging, asymptomatic lesion on sun-exposed skin, particularly the face, scalp, ears, neck, or upper trunk. The nodular subtype appears as a translucent or pearly papule or nodule with surface telangiectasias and often ulcerates centrally, forming a characteristic "rodent ulcer." Superficial BCCs present as well-demarcated, scaly, erythematous patches, often confused with eczema or psoriasis. Morpheaform or sclerosing subtypes are less conspicuous and appear as scar-like, indurated plaques with ill-defined borders, making them difficult to recognize clinically and prone to subclinical extension. Pigmented BCCs contain melanin and may resemble melanocytic lesions. Lesions may bleed, crust, or fail to heal despite conservative wound care. .
Risk Factors
The predominant risk factor for BCC is chronic exposure to ultraviolet radiation, particularly in individuals with fair skin (Fitzpatrick types I–II), light-colored eyes, and red or blond hair. Intermittent intense sun exposure during childhood and adolescence has a disproportionately high impact on later risk. Additional factors include advanced age, male sex, immunosuppression (such as in solid organ transplant recipients or patients on chronic immunomodulatory therapy), ionizing radiation exposure, arsenic ingestion, chronic inflammatory skin diseases, and genetic syndromes like basal cell nevus syndrome. A prior history of BCC or other non-melanoma skin cancers significantly increases the risk of developing additional lesions, as does occupational or recreational sun exposure.
Diagnosis
The diagnosis of BCC is primarily clinical, guided by characteristic morphology and history. Dermoscopy enhances diagnostic accuracy by revealing arborizing vessels, ovoid nests, blue-gray globules, and ulceration. Confirmatory diagnosis requires a skin biopsy—shave, punch, or excisional—depending on lesion size and location. Histopathologic evaluation demonstrates nests or cords of basaloid cells with peripheral palisading and retraction artifacts in a mucinous stroma. Subtypes (nodular, superficial, morpheaform, infiltrative, pigmented) have distinct histologic patterns with implications for prognosis and treatment. Imaging is not routinely required but may be indicated in large, recurrent, or high-risk tumors to evaluate deep tissue involvement, especially in periocular, nasal, or auricular locations.
Treatment
Treatment is selected based on lesion subtype, size, location, and patient-specific factors. Standard surgical excision with 4–6 mm margins is appropriate for most low-risk BCCs and has a cure rate of approximately 95%. Mohs micrographic surgery is the gold standard for high-risk, recurrent, or anatomically sensitive tumors due to its tissue-sparing nature and complete margin control, yielding cure rates exceeding 99%. Curettage and electrodesiccation is an option for low-risk, superficial lesions but is operator-dependent and not appropriate for aggressive subtypes. Superficial BCCs can also be treated with topical therapies such as 5-fluorouracil or imiquimod, though these have lower cure rates and are generally reserved for non-facial lesions. Cryotherapy and photodynamic therapy are additional options for select superficial tumors. Radiation therapy may be used in non-surgical candidates or elderly patients but carries a risk of long-term dermal atrophy and secondary malignancies. For advanced, locally invasive, or metastatic BCC, targeted systemic therapy with Hedgehog pathway inhibitors like vismodegib or sonidegib is indicated. These agents act on SMO to block downstream signaling, but adverse effects such as dysgeusia, muscle cramps, and alopecia often limit long-term use.
Outlook
With appropriate treatment, the prognosis for BCC is excellent. The five-year cure rate exceeds 95% for most cases, and metastasis is exceedingly rare, occurring in less than 0.5% of cases even with large or neglected tumors. Local recurrence is uncommon when complete excision is achieved but is more likely in lesions treated with non-surgical modalities or in high-risk subtypes. Patients with a history of BCC are at increased risk of developing subsequent BCCs or other cutaneous malignancies, necessitating ongoing surveillance. Morpheaform and infiltrative subtypes have higher recurrence rates and are associated with greater tissue destruction and cosmetic morbidity.
Complications
If inadequately treated, BCC can infiltrate surrounding tissues including muscle, cartilage, and bone, particularly in the head and neck. Perineural invasion, although rare, can result in pain and cranial neuropathies. Recurrent or aggressive subtypes pose increased surgical complexity, requiring more extensive excisions or reconstructive procedures. Cosmetic deformity, especially in periocular, nasal, and auricular regions, can impact quality of life. Radiation and systemic therapy carry their own adverse effect profiles, and lifelong surveillance is often required.
Prevention
Primary prevention hinges on minimizing UV exposure through sunscreen application, seeking shade, wearing UV-protective clothing, and avoiding indoor tanning. Early-life sun protection is particularly impactful in reducing lifetime BCC risk. Secondary prevention includes periodic dermatologic screening for individuals with significant sun exposure history, prior skin cancers, or genetic predispositions. For individuals with field cancerization, chemoprevention with topical 5-fluorouracil, imiquimod, or nicotinamide supplementation may be considered under specialist guidance. Immunocompromised patients require more vigilant preventive strategies due to heightened risk.
Support
Patients with BCC should be counseled on regular full-body skin checks, both self-performed and clinician-administered, at least annually or more frequently based on risk. Education on sun-safe behaviors is essential, including routine use of broad-spectrum sunscreen with SPF ≥30, wearing protective clothing, and avoiding outdoor activities during peak UV hours. Psychological support may be warranted for patients with multiple lesions or those undergoing disfiguring surgical procedures. Use of mobile dermatologic apps and photography to monitor lesions can facilitate early detection of recurrences or new tumors.
Sources
The information presented above is supported by reputable medical sources and research publications. These references provide additional clinical insights and evidence-based findings for healthcare professionals and individuals seeking comprehensive understanding of this medical condition.
